HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shinotoh, H. Articles by Tsui, J. Search for Related Content PubMed PubMed Citation Articles by Shinotoh, H. Articles by Tsui, J.

Lamotrigine trial in idiopathic parkinsonism

A double-blind, placebo-controlled, crossover study

From the Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, BC, Canada.

Increased glutamatergic transmission in the basal ganglia is implicated in the pathophysiology of idiopathic parkinsonism (IP). We investigated the effects of lamotrigine (LTG), a glutamate-release inhibitor, in the symptomatic treatment of IP in two double-blind, placebo-controlled studies. Single doses of L-dopdcarbidopa (equal to 50% of the usual morning dose) were administered together with either LTG (100, 200, or 400 mg) or two random placebo doses in 14 patients with IP. The patients were assessed using the Modified Columbia Rating Scale (MCRS) and the Purdue Pegboard Test (PPBT) at multiple intervals over 8 hours. There were no significant differences between the placebo doses and the three doses of LTG on the MCRS and PPBT scores. In a 3-month study, 12 patients took LTG titrated up to 400 mg or placebo with their antiparkinsonian medication for 3 months and were then crossed over. Nine of 12 patients did not complete the study because of dyskinesia (n = 2), hallucinations (n = 31, and deterioration of parkinsonian symptoms (n = 4) on LTG. There was no significant difference between placebo and LTG on the MCRS and PPBT in the three patients who completed the study. The results failed to demonstrate any symptomatically beneficial effects of LTG in IP.

This article has been cited by other articles:

				C Zadikoff, R P Munhoz, A N Asante, N Politzer, R Wennberg, P Carlen, and A Lang Movement disorders in patients taking anticonvulsants J. Neurol. Neurosurg. Psychiatry, February 1, 2007; 78(2): 147 - 151. [Abstract] [Full Text] [PDF]

				F. Stocchi, L. Vacca, P. Grassini, M. F. De Pandis, G. Battaglia, C. Cattaneo, and R. G. Fariello Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology, October 10, 2006; 67(7 Suppl 2): S24 - S29. [Abstract] [Full Text]

				T. A. Zesiewicz, K. L. Sullivan, and R. A. Hauser Chorea Induced by Lamotrigine J Child Neurol, April 1, 2006; 21(4): 357 - 357. [PDF]

				J. H. Cross Reply to Zesiewicz et al J Child Neurol, April 1, 2006; 21(4): 357 - 358. [PDF]

				T. A. Zesiewicz, K. L. Sullivan, and R. A. Hauser Chorea Induced by Lamotrigine J Child Neurol, April 1, 2006; 21(4): 357 - 357. [PDF]

				J. H. Cross Reply to Zesiewicz et al. J Child Neurol, April 1, 2006; 21(4): 357 - 358. [PDF]

				J. M. Pellock Overview of Lamotrigine and the New Antiepileptic Drugs: The Challenge J Child Neurol, November 1, 1997; 12(1_suppl): S48 - S52. [Abstract] [PDF]